Too often, recruiters are more clear on what a position will “do” rather than what it will “achieve”.Outlining tasks and responsibilities takes priority over goals and impact.But to attract top talent, you need to define and explain what success looks…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Mitsubishi Tanabe to Focus on Sales Turnaround for Canaglu, Eyes Diabetes and Nephrology Sales of 100 Bil. Yen
August 17, 2016
-
REGULATORY MHLW OKs First Generics for Tracleer, 6 Other APIs towards December Listing
August 16, 2016
-
BUSINESS Teijin Gets Japan Rights to Versartis’ Growth Hormone Deficiency Treatment
August 15, 2016
-
REGULATORY MHLW Study Group to Look at Measures to Popularize Biosimilars, Increase Efficiency in Development and Manufacturing
August 12, 2016
-
REGULATORY Startup Promotion Guide to Support Major Companies as well: MHLW Official
August 10, 2016
-
REGULATORY JMA, MHLW Say Possible Opdivo Re-Pricing Is Emergency Step, Won’t Make It Slippery Slope to Annual Revisions
August 9, 2016
-
ORGANIZATION EFPIA Japan Calls for Relaxation of Japanese Vaccine Regulations: Vaccine Subcommittee Head
August 9, 2016
-
REGULATORY MHLW Panel OKs Opdivo for RCC, ASKA’s Hepatic Encephalopathy Drug
August 8, 2016
-
INTERVIEW Japan Biosimilar Association Aims to Share Knowledge and Experience to Popularize the Use of Biosimilars: Director General
August 5, 2016
-
REGULATORY Kipres/Singulair to Face Generic Onslaught in Dec.; Competition to Hit Tracleer, Too
August 4, 2016
-
ACADEMIA 3 Scientific Societies to Set Up HBOC Body to Build BRCA Gene Database
August 4, 2016
-
REGULATORY MHLW to Gauge Possible Deregulation of Plasma Export Restriction towards FY2018: Blood Division Chief
August 3, 2016
-
BUSINESS Japan Market Grows in April-June on Hep C Meds, Opdivo: IMS
August 2, 2016
-
BUSINESS Takeda to Revamp R&D Organization, Eyes Consolidated Research Sites in Japan, US
August 1, 2016
-
REGULATORY Pricy Meds Issue Takes a Step Forward with 2-Faceted Proposal
July 29, 2016
-
REGULATORY Chuikyo to Discuss Out-of-Cycle Re-Pricing for Opdivo, but JMA Turns Wary
July 28, 2016
-
BUSINESS Damage Suit Filed over HPV Vaccines; MSD Says Claims Scientifically Unfounded
July 28, 2016
-
REGULATORY MHLW to Canvass Drug Makers’ Opinions on Real-World Roles of “3 Key Officers”: Pharma Safety Head
July 27, 2016
-
REGULATORY ICH Clinical Trial Guidelines Allow Flexibility on Number of Japanese Subjects Needed: PMDA Official
July 26, 2016
-
REGULATORY MRSA Infections Add 190 Billion Yen Annually to Medical Expenditure at DPC Hospitals: MHLW Study Group
July 25, 2016
ページ
Pharmaceutical companies are giving high marks to Japan’s drug pricing reform for FY2024. According to a survey conducted by Jiho, 51% of all respondents expressed a positive opinion of the reform, saying that they were “somewhat satisfied” with it. The…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…